Enovis (NYSE:ENOV) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Enovis from a "buy" to a "hold" in a research note issued on Saturday.
• Despite the downgrade, the consensus rating remains Buy with a consensus target price of $47.43 and an analyst mix of 2 Strong Buy, 7 Buy, and 1 Sell.
• Enovis reported Q results with $0.95 EPS (beat $0.81 est.) but revenue of $575.8M slightly missed expectations; it set FY2026 guidance of 3.520–3.730 EPS and its shares trade around $23.58 (1‑year range $21–$37.85).

Enovis (NYSE:ENOV - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Saturday.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Enovis in a report on Friday, April 10th. Zacks Research raised Enovis from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 4th. BTIG Research raised their target price on Enovis from $41.00 to $43.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Needham & Company LLC raised their target price on Enovis from $49.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Finally, Wells Fargo & Company raised Enovis to a "strong-buy" rating in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $47.43.

Enovis Price Performance

NYSE:ENOV opened at $23.58 on Friday. Enovis has a one year low of $21.00 and a one year high of $37.85. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a market cap of $1.36 billion, a PE ratio of -1.14 and a beta of 1.41. The stock has a 50 day moving average price of $23.70 and a 200 day moving average price of $25.99.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The firm had revenue of $575.76 million during the quarter, compared to analysts' expectations of $584.30 million. During the same quarter last year, the firm earned $0.98 earnings per share. The business's revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 3.62 EPS for the current fiscal year.

Insider Transactions at Enovis

In other Enovis news, insider Oliver Engert bought 1,000 shares of the business's stock in a transaction on Friday, February 27th. The stock was bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider directly owned 43,640 shares in the company, valued at $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders acquired a total of 5,000 shares of company stock worth $121,983 over the last ninety days. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently modified their holdings of the company. Fifth Third Bancorp grew its stake in shares of Enovis by 50,442.8% in the first quarter. Fifth Third Bancorp now owns 83,901 shares of the company's stock valued at $1,909,000 after buying an additional 83,735 shares in the last quarter. Bernzott Capital Advisors grew its stake in shares of Enovis by 47.4% in the first quarter. Bernzott Capital Advisors now owns 294,125 shares of the company's stock valued at $6,691,000 after buying an additional 94,529 shares in the last quarter. Counterpoint Mutual Funds LLC acquired a new stake in shares of Enovis in the first quarter valued at $564,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Enovis in the first quarter valued at $429,000. Finally, Inspire Investing LLC acquired a new stake in shares of Enovis in the first quarter valued at $523,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.